期刊文献+

解读干细胞管理征求意见稿 被引量:1

下载PDF
导出
摘要 近年来,干细胞治疗在中国被视作一种产业。一些生物技术公司与医院合作,以研究的名义进行干细胞治疗,任意夸大治疗效果,并向患者收取高额费用。
作者 睢素利
出处 《中国医院院长》 2013年第9期75-75,共1页 China Hospital CEO
  • 相关文献

同被引文献29

  • 1Herberts CA, Kwa MS, Hennsen HP. Risk factors in the development of stem cell therapyEJ~. Transl Med, 2011,9(1) :29-44.
  • 2Von Tigerstrom B. Product regulation and the clinical translation of stem cell research[-J~. Stem Cell Rev, 2009,5(2) .. 135-139.
  • 3KeIlathur SN, Lou HX. Cell and tissue therapy regu- lation~ worldwide status and harmonization EJ'~. Bio logicals, 2012,40 ( 3 ) : 222-224.
  • 4Future Science Group. European Medicines Agency, CAT Secretariat ~ US Food and Drug Administra- tionEJ-I. Regen Med,2011,6(6 suppl) :90-96.
  • 5Committee for Advanced Therapies. Challenges with advanced therapy medicinal products and how to meet themrJ~. Nat Rev Drug Discov, 2010,9 (3) : 195-201.
  • 6Future Science Group. Global Update:Japan[J]. Re- gen Med,2011,6(6) :160-162.
  • 7Kawakami M,Sipp D,Kato K. Regulatory impacts onstem ceil research in Japan~-J]. Cell Stem Cei1,2010,7 (6) :415-418.
  • 8Oh IH. Regulatory issues in stem cell therapeutics in Korea:efficacy or efficiency? [-J-]. Korean J Hematol, 2012,47(2) ~ 87-89.
  • 9Mi-Kyung Kim. Oversight framework overoocyte pro- curement for somatic cell nuclear transfer~ compara- tive analysis of the Hwang Woo Suk case under South Korean bioethics law and U. S. guidelines for human embryonic stem cell research[-J~. Theor Med Bioeth, 2009,30(1) :367-384.
  • 10萧驷.诺奖开启4000亿美元干细胞产业大门[EB/OL].[2012-10-10].http://www.bioon.com/indus-try/reviews/531128.shtml.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部